Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.
Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D.
Veeranki OL, et al. Among authors: tetzlaff m.
Oncotarget. 2019 Jul 23;10(45):4703-4718. doi: 10.18632/oncotarget.27095. eCollection 2019 Jul 23.
Oncotarget. 2019.
PMID: 31384397
Free PMC article.